Clinical Trial

A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-08-22; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2025-10-02
Trial Details
NCT Number NCT07140614
Lead Sponsor Novartis Pharmaceuticals
Conditions Charcot-Marie-Tooth Disease, Type 1A
Enrollment 28 participants
Start Date 2025-09-30
Primary Completion 2028-02-25 (estimated)
Study Completion 2028-02-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-29